C. Davies

发表

Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C.

H. Tian, J. Jiang, C. Pan, 2003, Diabetes technology & therapeutics.

Breast-cancer adjuvant therapy with zoledronic acid.

W. Gregory, D. Cameron, D. Dodwell, 2011, The New England journal of medicine.

Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer

D. Cameron, D. Dodwell, R. Bell, 2011, Breast Cancer Research and Treatment.

Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study

G. Shaddick, A. Barton, L. Coates, 2018, Rheumatology.

Adjuvant therapy with zoledronic acid (AZURE-BIG 01/04): The influence of menopausal status and age on treatment effects.

W. Gregory, D. Cameron, D. Dodwell, 2012 .

The 'Switch’ study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug

L. Sharples, D. Scott, P. Emery, 2014, BMC Musculoskeletal Disorders.

Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.

L. Sharples, P. Emery, C. McCabe, 2018, Health technology assessment.

Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)

G. Burmester, P. Leszczyński, M. Bao, 2014, Annals of the rheumatic diseases.

Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.

L. Sharples, P. Emery, C. McCabe, 2018, Health technology assessment.